211 related articles for article (PubMed ID: 36413364)
61. Variations in Age-Adjusted Prostate Cancer Incidence Rates by Race and Ethnicity After Changes in Prostate-Specific Antigen Screening Recommendation.
Lai SM; Keighley J; Garimella S; Enko M; Parker WP
JAMA Netw Open; 2022 Nov; 5(11):e2240657. PubMed ID: 36342715
[TBL] [Abstract][Full Text] [Related]
62. Poor Follow-up After Elevated Prostate-specific Antigen Tests: A Population-based Cohort Study.
Aly M; Clements M; Weibull CE; Nordström T; Näslund E; Adolfsson J; Grönberg H
Eur Urol Focus; 2019 Sep; 5(5):842-848. PubMed ID: 29433987
[TBL] [Abstract][Full Text] [Related]
63. An exploration of screening practices for prostate cancer and the associated community expenditure.
Perkins JJ; Sanson-Fisher RW; Clarke SJ; Youman P
Br J Urol; 1998 Oct; 82(4):524-9. PubMed ID: 9806181
[TBL] [Abstract][Full Text] [Related]
64. Use of the prostate-specific antigen test among men aged 75 years or older in the United States: 2006 Behavioral Risk Factor Surveillance System.
Li J; Zhao G; Pollack LA; Smith JL; Joseph DA
Prev Chronic Dis; 2010 Jul; 7(4):A84. PubMed ID: 20550842
[TBL] [Abstract][Full Text] [Related]
65. Recommended prostate-specific antigen testing intervals for the detection of curable prostate cancer.
Carter HB; Epstein JI; Chan DW; Fozard JL; Pearson JD
JAMA; 1997 May; 277(18):1456-60. PubMed ID: 9145718
[TBL] [Abstract][Full Text] [Related]
66. Detection of prostate cancer via biopsy in the Medicare-SEER population during the PSA era.
Welch HG; Fisher ES; Gottlieb DJ; Barry MJ
J Natl Cancer Inst; 2007 Sep; 99(18):1395-400. PubMed ID: 17848671
[TBL] [Abstract][Full Text] [Related]
67. Is additional testing necessary in men with prostate-specific antigen levels of 1.0 ng/mL or less in a population-based screening setting? (ERSPC, section Rotterdam).
Roobol MJ; Roobol DW; Schröder FH
Urology; 2005 Feb; 65(2):343-6. PubMed ID: 15708050
[TBL] [Abstract][Full Text] [Related]
68. Comparison of Low-Value Services Among Medicare Advantage and Traditional Medicare Beneficiaries.
Boudreau E; Schwartz R; Schwartz AL; Navathe AS; Caplan A; Li Y; Blink A; Racsa P; Antol DD; Erwin CJ; Shrank WH; Powers BW
JAMA Health Forum; 2022 Sep; 3(9):e222935. PubMed ID: 36218933
[TBL] [Abstract][Full Text] [Related]
69. Association Between Receipt of Cancer Screening and All-Cause Mortality in Older Adults.
Schoenborn NL; Sheehan OC; Roth DL; Cidav T; Huang J; Chung SE; Zhang T; Lee S; Xue QL; Boyd CM
JAMA Netw Open; 2021 Jun; 4(6):e2112062. PubMed ID: 34061202
[TBL] [Abstract][Full Text] [Related]
70. Deliberative democracy and cancer screening consent: a randomised control trial of the effect of a community jury on men's knowledge about and intentions to participate in PSA screening.
Thomas R; Glasziou P; Rychetnik L; Mackenzie G; Gardiner R; Doust J
BMJ Open; 2014 Dec; 4(12):e005691. PubMed ID: 25539779
[TBL] [Abstract][Full Text] [Related]
71. Use of low free to total PSA ratio in prostate cancer screening: detection rates, clinical and pathological findings in Brazilian men with serum PSA levels <4.0 ng/mL.
Faria EF; Carvalhal GF; dos Reis RB; Tobias-Machado M; Vieira RA; Reis LO; Nogueira L; Machado RD; Freitas CH; Magnabosco WJ; Mauad EC; Carvalho AL
BJU Int; 2012 Dec; 110(11 Pt B):E653-7. PubMed ID: 22892057
[TBL] [Abstract][Full Text] [Related]
72. The role of increasing detection in the rising incidence of prostate cancer.
Potosky AL; Miller BA; Albertsen PC; Kramer BS
JAMA; 1995 Feb; 273(7):548-52. PubMed ID: 7530782
[TBL] [Abstract][Full Text] [Related]
73. Testing and referral patterns in the years surrounding the US Preventive Services Task Force recommendation against prostate-specific antigen screening.
Hutchinson R; Akhtar A; Haridas J; Bhat D; Roehrborn C; Lotan Y
Cancer; 2016 Dec; 122(24):3785-3793. PubMed ID: 27658175
[TBL] [Abstract][Full Text] [Related]
74. Prostate-specific antigen testing of older men.
Carter HB; Landis PK; Metter EJ; Fleisher LA; Pearson JD
J Natl Cancer Inst; 1999 Oct; 91(20):1733-7. PubMed ID: 10528023
[TBL] [Abstract][Full Text] [Related]
75. Current and projected annual direct costs of screening asymptomatic men for prostate cancer using prostate-specific antigen.
Krahn MD; Coombs A; Levy IG
CMAJ; 1999 Jan; 160(1):49-57. PubMed ID: 9934343
[TBL] [Abstract][Full Text] [Related]
76. Screening for Prostate Cancer Starting at Age 50-54 Years. A Population-based Cohort Study.
Carlsson S; Assel M; Ulmert D; Gerdtsson A; Hugosson J; Vickers A; Lilja H
Eur Urol; 2017 Jan; 71(1):46-52. PubMed ID: 27084245
[TBL] [Abstract][Full Text] [Related]
77. Impact of Accountable Care Organizations on Diagnostic Testing for Prostate Cancer.
Luckenbaugh AN; Hollenbeck BK; Kaufman SR; Yan P; Herrel LA; Skolarus TA; Norton EC; Schroeck FR; Jacobs BL; Miller DC; Hollingsworth JM; Shahinian VB; Borza T
Urology; 2018 Jun; 116():68-75. PubMed ID: 29630957
[TBL] [Abstract][Full Text] [Related]
78. What happens after an elevated PSA test: the experience of 13,591 veterans.
Zeliadt SB; Hoffman RM; Etzioni R; Ginger VA; Lin DW
J Gen Intern Med; 2010 Nov; 25(11):1205-10. PubMed ID: 20697965
[TBL] [Abstract][Full Text] [Related]
79. Prostate-specific antigen testing in Australia and association with prostate cancer incidence in New South Wales.
Smith DP; Armstrong BK
Med J Aust; 1998 Jul; 169(1):17-20. PubMed ID: 9695696
[TBL] [Abstract][Full Text] [Related]
80. Prostate-specific antigen values at the time of prostate cancer diagnosis in African-American men.
Moul JW; Sesterhenn IA; Connelly RR; Douglas T; Srivastava S; Mostofi FK; McLeod DG
JAMA; 1995 Oct; 274(16):1277-81. PubMed ID: 7563532
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
